Cellular Senescence in Lung Cancer: Molecular Mechanisms and Therapeutic Interventions.

Jha, SK; De Rubis, G; Devkota, SR; Zhang, Y; Adhikari, R; Jha, LA; Bhattacharya, K; Mehndiratta, S; Gupta, G; Singh, SK; Panth, N; Dua, K; Hansbro, PM; Paudel, KR

Cellular Senescence in Lung Cancer: Molecular Mechanisms and Therapeutic Interventions.

Jha, SK De Rubis, G Devkota, SR Zhang, Y Adhikari, R Jha, LA Bhattacharya, K Mehndiratta, S Gupta, G Singh, SK Panth, N Dua, K

Hansbro, PM Paudel, KR

Permalink

Publisher:: Elsevier BV
Publication Type:: Journal Article
Citation:: Ageing Res Rev, 2024, pp. 102315
Issue Date:: 2024-04-26

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

Adobe PDF

Download Published versionAdobe PDF (5.29 MB)

View on publisher's site

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	Jha, SK
dc.contributor.author	De Rubis, G
dc.contributor.author	Devkota, SR
dc.contributor.author	Zhang, Y
dc.contributor.author	Adhikari, R
dc.contributor.author	Jha, LA
dc.contributor.author	Bhattacharya, K
dc.contributor.author	Mehndiratta, S
dc.contributor.author	Gupta, G
dc.contributor.author	Singh, SK
dc.contributor.author	Panth, N
dc.contributor.author	Dua, K https://orcid.org/0000-0002-7507-1159
dc.contributor.author	Hansbro, PM
dc.contributor.author	Paudel, KR
dc.date.accessioned	2024-05-03T04:28:32Z
dc.date.available	2024-04-23
dc.date.available	2024-05-03T04:28:32Z
dc.date.issued	2024-04-26
dc.identifier.citation	Ageing Res Rev, 2024, pp. 102315
dc.identifier.issn	1568-1637
dc.identifier.issn	1872-9649
dc.identifier.uri	http://hdl.handle.net/10453/178612
dc.description.abstract	Lung cancer stands as the primary contributor to cancer-related fatalities worldwide, affecting both genders. Two primary types exist where non-small cell lung cancer (NSCLC), accounts for 80-85% and SCLC accounts for 10-15% of cases. NSCLC subtypes include adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Smoking, second-hand smoke, radon gas, asbestos, and other pollutants, genetic predisposition, and COPD are lung cancer risk factors. On the other hand, stresses such as DNA damage, telomere shortening, and oncogene activation cause a prolonged cell cycle halt, known as senescence. Despite its initial role as a tumor-suppressing mechanism that slows cell growth, excessive or improper control of this process can cause age-related diseases, including cancer. Cellular senescence has two purposes in lung cancer. Researchers report that senescence slows tumor growth by constraining multiplication of impaired cells. However, senescent cells also demonstrate the pro-inflammatory senescence-associated secretory phenotype (SASP), which is widely reported to promote cancer. This review will look at the role of cellular senescence in lung cancer, describe its diagnostic markers, ask about current treatments to control it, look at case studies and clinical trials that show how senescence-targeting therapies can be used in lung cancer, and talk about problems currently being faced, and possible solutions for the same in the future.
dc.format	Print-Electronic
dc.language	eng
dc.publisher	Elsevier BV
dc.relation.ispartof	Ageing Res Rev
dc.relation.isbasedon	10.1016/j.arr.2024.102315
dc.rights	info:eu-repo/semantics/openAccess
dc.subject	0601 Biochemistry and Cell Biology, 1103 Clinical Sciences, 1109 Neurosciences
dc.subject.classification	Gerontology
dc.subject.classification	3101 Biochemistry and cell biology
dc.subject.classification	3202 Clinical sciences
dc.subject.classification	3209 Neurosciences
dc.title	Cellular Senescence in Lung Cancer: Molecular Mechanisms and Therapeutic Interventions.
dc.type	Journal Article
utslib.location.activity	England
utslib.for	0601 Biochemistry and Cell Biology
utslib.for	1103 Clinical Sciences
utslib.for	1109 Neurosciences
pubs.organisational-group	University of Technology Sydney
pubs.organisational-group	University of Technology Sydney/Faculty of Health
pubs.organisational-group	University of Technology Sydney/Faculty of Science
pubs.organisational-group	University of Technology Sydney/Strength - CFI - Centre for Inflammation
utslib.copyright.status	open_access	*
dc.date.updated	2024-05-03T04:28:29Z
pubs.publication-status	Published online

Abstract:

Lung cancer stands as the primary contributor to cancer-related fatalities worldwide, affecting both genders. Two primary types exist where non-small cell lung cancer (NSCLC), accounts for 80-85% and SCLC accounts for 10-15% of cases. NSCLC subtypes include adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Smoking, second-hand smoke, radon gas, asbestos, and other pollutants, genetic predisposition, and COPD are lung cancer risk factors. On the other hand, stresses such as DNA damage, telomere shortening, and oncogene activation cause a prolonged cell cycle halt, known as senescence. Despite its initial role as a tumor-suppressing mechanism that slows cell growth, excessive or improper control of this process can cause age-related diseases, including cancer. Cellular senescence has two purposes in lung cancer. Researchers report that senescence slows tumor growth by constraining multiplication of impaired cells. However, senescent cells also demonstrate the pro-inflammatory senescence-associated secretory phenotype (SASP), which is widely reported to promote cancer. This review will look at the role of cellular senescence in lung cancer, describe its diagnostic markers, ask about current treatments to control it, look at case studies and clinical trials that show how senescence-targeting therapies can be used in lung cancer, and talk about problems currently being faced, and possible solutions for the same in the future.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/178612